Onyx pharma - In the Driver’s Seat, with Kyprolis Approval
An ‘Accelerated approval’ of Kyprolis (carfilzomib – CFZ, R, next-generation proteasome inhibitor) and better positioning of Nexavar (L, RCC, HCC, partnered with Bayer) in HCC after the setback to Brivanib (BMS, HCC) have swung the wind in Onyx’s (ONXX) favor. Kyprolis has the first mover advantage in catering to the unmet need in Relapsed and Refractory Multiple Myeloma – R/R MM. In the 2Q12, Nexavar reported modest growth of 4% (YoY) where sales grew 13% (YoY) in the US and flat growth in the ROW due to Fx impact, pricing pressure, rebates and healthcare reforms. ONXX has revised its FY12 guidance – increased costs with no change in sales guidance (Net product revenues: $840m-$860m). We see modest growth in… For more detail, please read our report released on 9th Aug. 2012, on Onyx Pharma titled “In the Driver’s Seat, with Kyprolis Approval”.
More Publications
Onyx Pharma – Kyprolis to Accelerate Growth
US$ 140.00
June 2012
4 pages
Onyx Pharma, Market Perform - M&A Rumors Fuel Investors Interest and Stock Movement
US$ 90.00
November 2011
6 pages
Onyx Pharma - Banking on Carfilzomib’s Approval or Acquisition!
US$ 90.00
March 2012
4 pages
ONYX PHARMA - Carfilzomib Approval - Now or Later?
US$ 140.00
November 2011
3 pages
ONYX PHARMA - Testing Time Ahead in the Hematological Cancer Space
US$ 140.00
September 2011
3 pages
